GlassScriptPhysician profile
Susan George
NPI 1609076751
$3,568.80
in general payments reported to CMS, 2019-2025
19 companies · $516 in 2025
The $516 reported for 2025 was more than what 77% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $417 · 2023: $1,796 · 2024: $392 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938 · Travel and Lodging: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.12 |
| Travel and Lodging | $765.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,174.34 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip, Cardiomems |
| Alnylam Pharmaceuticals INC. | $299.02 | 2023-2025 | Amvuttra, Onpattro |
| Pfizer INC. | $228.66 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.42 | 2021-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $128.03 | 2023-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $74.02 | 2022-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $72.28 | 2021-2024 | Wainua |
| Abbvie INC. | $61.85 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.86 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $51.02 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $50.76 | 2022-2024 | Optimizer, Optimizer |
| Abiomed | $43.74 | 2024 | Impella |
| Boston Scientific Corporation | $38.52 | 2023-2025 | Watchman, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $36.12 | 2021-2022 | |
| Dexcom, INC. | $31.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.28 | 2023-2025 | |
| Janssen Biotech, INC. | $23.90 | 2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $18.81 | 2025 | Spravato |
| Almatica Pharma LLC | $16.89 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.